GILD - Gilead Sciences, Inc Stock Analysis
Gilead Sciences, Inc (GILD) is a publicly traded company listed on the NASD. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 154.02B, generates annual revenue of 29.05B, and reports net income of 8.11B. As of the latest data, the stock is trading at 124.14 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company uses a significant amount of debt to finance its operations, which can boost returns but adds financial risk. The stock offers a moderate dividend yield (2.67%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.05), indicating current market sentiment. Institutional ownership is reported at 88.06%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 35.45%, trading within a 52-week range of 91.68 - 128.70.
GILD - Gilead Sciences, Inc
124.14
Analyst Consensus
Buy 4.05
GILD – Analyst Rating Summary
- Strong Buy: 10
- Buy: 19
- Hold: 8
- Sell: 0
- Strong Sell: 0
- Total Analysts: 37
| Index: | NDX, S&P 500 | P/E: | 19.23 | EPS (ttm): | 6.46 | Insider Own: | 0.21% | Shs Outstand: | 1.24B | Perf Week: | 1.26% |
| Market Cap: | 154.02B | Forward P/E: | 14.17 | EPS next Y: | 8.76 | Insider Trans: | -7.40% | Shs Float: | 1.24B | Perf Month: | 2.29% |
| Income(ttm): | 8.11B | PEG: | 0.54 | EPS next Q: | 1.85 | Inst Own: | 88.06% | Short Float: | 1.87% | Perf Quarter: | 1.08% |
| Revenue(ttm): | 29.05B | P/S: | 5.30 | EPS this Y: | 76.24% | Inst Trans: | -0.38% | Short Ratio: | 3.33 | Perf Half Y: | 14.65% |
| Book/sh: | 17.34 | P/B: | 7.16 | EPS next Y: | 7.62% | ROA: | 14.35% | Short Interest: | 23.15M | Perf Year: | 35.45% |
| Cash/sh: | 7.40 | P/C: | 16.79 | EPS next 5Y: | 26.36% | ROE: | 40.53% | 52W Range: | 91.68 - 128.70 | Perf YTD: | 1.14% |
| Dividend Est.: | 3.32 (2.67%) | P/FCF: | 16.81 | EPS past 3/5Y: | -57.36% -38.13% | ROIC: | 18.57% | 52W High: | 128.70 -3.54% | Beta: | 0.37 |
| Dividend TTM: | 3.16 (2.55%) | Quick Ratio: | 1.31 | Sales past 3/5Y: | 1.62% 5.17% | Gross Margin: | 78.69% | 52W Low: | 91.68 35.40% | Perf 5Y: | 99.97% |
| Dividend Ex-Date: | Dec 15, 2025 | Current Ratio: | 1.45 | EPS Y/Y TTM: | 6407.19% | Oper. Margin: | 39.02% | RSI (14): | 53.12 | Volatility: | 2.80% 2.42% |
| Employees: | 17600 | Debt/Eq: | 1.16 | Sales Y/Y TTM: | 2.76% | Profit Margin: | 27.91% | Recom: | 1.62 | Target Price: | 136.48 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 1.03 | EPS Q/Q: | 142.22% | Payout: | 805.23% | Rel Volume: | 1.31 | Prev Close: | 124.91 |
| Sales Surprise: | 4.35% | EPS Surprise: | 15.85% | Sales Q/Q: | 3.36% | Earnings: | Oct 30 AMC | Avg Volume: | 6.95M | Price: | 124.14 |
| SMA20: | 0.89% | SMA50: | 0.79% | SMA200: | 8.45% | Undervalued: 9.94% | Volume: | 9,077,538 | Change: | -0.62% | |
Graham Classic formula value: 355.13
(P/E=8 * 1g) Min value: 199.32
(current P/E * 2g) Max value: 417.37
Average value: 323.94
About Gilead Sciences, Inc
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.